HOME >> MEDICINE >> NEWS
Other highlights in the April 21 JNCI

t density in healthy women has not been known. To investigate this, Jack Cuzick, Ph.D., of Cancer Research UK in London, and colleagues analyzed mammograms from 818 breast cancer-free women from the International Breast Cancer Intervention Study 1, a trial that tested tamoxifen's ability to prevent breast cancer in healthy women at high risk of the disease.

Treatment with tamoxifen was associated with reduced breast density, most of which occurred within the first 18 months of treatment. In women aged 45 years and younger, breast density was reduced by 13.4% on average compared with only 1.1% in women older than 55 years. The researchers hypothesize that premenopausal women experienced a larger reduction because premenopausal estrogen levels are higher and so the antiestrogenic effect of tamoxifen will be greater.

Contact: Press Office, Cancer Research UK, +44 (0) 207 061 8300, pressoffice@cancer.org.uk

Low Categories of Benign Breast Disease Still Increase Risk of Breast Cancer

There are several breast abnormalities that are not cancerous, but some of these benign conditions are associated with a greater risk of breast cancer than others. A new study has found that even women with low-category benign breast diseases are at an increased risk of breast cancer compared with women without the disease.

Jiping Wang, M.D., Ph.D., of the University of Pittsburgh, and colleagues looked at medical records for 11,307 women from the Breast Cancer Prevention Trial, 1376 of whom had the low-category benign breast disease. Women with the disease were 60% more likely than women without the disease to develop invasive breast cancer. Women with benign breast disease aged 50 years or older had a 95% increased risk of developing invasive breast cancer compared to women without benign breast disease.

Contact: Lori Garvey, National Surgical Breast and Bowel Project, (412)330-4621, <
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
20-Apr-2004


Page: 1 2 3 4

Related medicine news :

1. Other highlights in the March 16 JNCI
2. Other highlights in the March 2 JNCI
3. Other highlights in the February 2 JNCI
4. Other highlights in the January 19 JNCI
5. Other highlights in the December 15 JNCI
6. Other highlights in the December 1 JNCI
7. Other highlights in the September 15 JNCI
8. Other highlights in the April 7 JNCI
9. Other highlights in the January 7 issue of JNCI
10. Other highlights in the December 3 issue of JNCI
11. Other highlights in the November 19 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Other highlights the April JNCI

(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... According to ... been developed that changes color when subjected to an impact force that is great ... be implemented in helmets or other sporting equipment so that coaches or officials would ...
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article published August ... Association presented data showing that it is safe for pregnant women to undergo local ... had undergone local anesthesia with a group that hadn’t, researchers were able to determine ...
(Date:9/4/2015)... ... September 04, 2015 , ... On ... has effectively doubled the size of its annual health tech innovation program. Now ... digital health startups to compete for cash and prizes to advance their technologies ...
(Date:9/4/2015)... , ... September 04, 2015 , ... With TransCel from ... mouse all within Final Cut Pro X. With TransCel users have full control over ... width, background color, speed method, frame color, inner color, text, and more. With TransCel ...
(Date:9/4/2015)... ... 2015 , ... Mile High Connects today releases “First and Last Mile Connections,” ... sidewalks, bike paths, and other vital supports severely limit access to public transportation for ... dollars to expand public transit, there’s very little support for safe and convenient access ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Missed Connections in Metro Denver Transit 2
(Date:9/4/2015)... , Sept. 4, 2015  Janssen Research & ... and Drug Administration (FDA) has accepted for Priority ... as a treatment for patients with multiple myeloma ... (PI) and an immunomodulatory agent (IMiD), or who ... therapy, including a PI and an IMiD. This ...
(Date:9/4/2015)... -- Fair Rate Funding, a lawsuit funding firm located in ... increase in lawsuit filings in connection with the blood thinning ... Philadelphia Court of Common Pleas has ... Louisiana multi---district litigation (MDL), located in ... Louisiana , the filings are also on the ...
(Date:9/4/2015)... HILL, N.C. , Sept. 4, 2015 /PRNewswire/ ... Liaisons (MSLs) and other Field-Based Medical Specialists (FBMS) ... key opinion leaders, and thought leaders in critical ... effectiveness of their field-based teams, companies are expanding ... order to align countries with corporate objectives and ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2
Cached News: